EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Triple-Drug cocktail takes aim at rare, aggressive cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC